Diagnostics company Summit Biolabs Inc stated on Wednesday that it plans to conduct research, development and commercialization of saliva liquid-biopsy tests for early cancer detection and diagnosis of COVID-19 and other viral contagions under a broad strategic collaboration with the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus.
The CCPM reportedly holds one of the largest research biobanks in the US with clinical data from more than 8.7m de-identified patient records and plans to integrate the data with personalized genomic information.
Using simple, non-invasive saliva liquid-biopsy technology developed by Dr Shi-Long Lu and colleagues at the University of Colorado Anschutz Medical Campus, Summit Biolabs is developing breakthrough tests to improve the detection of COVID-19 and to advance the early detection of human cancers, including head & neck cancer.
In conjunction, Summit Biolabs' research foundation and competency in head & neck cancer diagnosis enabled the company's pivot to saliva-based testing for COVID-19.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval